2. Academic Validation
  3. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential

Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selective ligands and clinical potential

  • Steroids. 2014 Nov;90:13-29. doi: 10.1016/j.steroids.2014.06.012.
Ilaria Paterni 1,  Carlotta Granchi 1,  John A Katzenellenbogen 2,  Filippo Minutolo 3
Affiliations

Affiliations

  • 1 Dipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy.
  • 2 Department of Chemistry, University of Illinois, 600 S. Mathews Avenue, Urbana, IL 61801, USA.
  • 3 Dipartimento di Farmacia, Università di Pisa, Via Bonanno 6, 56126 Pisa, Italy. Electronic address: [email protected].
PMID: 24971815 DOI: 10.1016/j.steroids.2014.06.012
Abstract

Estrogen receptors alpha (ERα) and beta (ERβ) are nuclear transcription factors that are involved in the regulation of many complex physiological processes in humans. Modulation of these receptors by prospective therapeutic agents is currently being considered for prevention and treatment of a wide variety of pathological conditions, such as, Cancer, metabolic and cardiovascular diseases, neurodegeneration, inflammation, and osteoporosis. This review provides an overview and update of compounds that have been recently reported as modulators of ERs, with a particular focus on their potential clinical applications.

Keywords

Agonists; Antagonists; Estrogen receptor subtype α; Estrogen receptor subtype β; Modulators; Therapeutic applications.

Figures